Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 2, 2004, Pages 365-373

  Porceddu, Sandro V ^a,b   Campbell, Belinda ^a   Rischin, Danny ^a   Corry, June ^a   Weih, Leann ^a   Guerrieri, Mario ^a   Grossi, Marissa ^a   Peters, Lester J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Chemotherapy; Head and neck; Postoperative; Radiotherapy; Squamous cell carcinoma

Indexed keywords

DISEASES; PATIENT TREATMENT; RADIOTHERAPY; SURGERY;

CARBOPLATIN; CHEMORADIOTHERAPHY; CISPLATIN;

CHEMOTHERAPY;

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGUS STRICTURE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; HEAD AND NECK CANCER; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; LUNG INFECTION; MALE; MOUTH CAVITY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION INJURY; RECURRENT CANCER; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NECK DISSECTION; RADIATION INJURIES; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 4544262940     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.03.011     Document Type: Article

References (25)

1. Peters L.J., Goepfert H., Ang K.K., et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer First report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 26:1993;3-11
2. Ang K.K., Trotti A., Brown B., et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 51:2001;571-578
3. Begg A. Cisplatin and radiation Interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys. 19:1990;1183-1189
4. MACH-NC (Meta-Analysis of Chemotherapy in Head and Neck Cancer) Collaborative Group, Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous cell cancer Three meta-analysis of updated individual data. Lancet. 355:2000;949-955
5. Bachaud J.M., Cohen-Jonathan E., Alzieu C., et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma Final report of a randomized trial. Int J Radiat Oncol Biol Phys. 36:1996;999-1004
6. Sobin L.H., Wittekind C. TNM classification of malignant tumours. 5th ed.:1997;Wiley-Liss, New York
7. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 7:1989;1748-1756
8. Millward M.J., Webster L.K., Toner G.C., et al. Carboplatin dosing based on measurement of renal function - Experience at the Peter MacCallum Cancer Institute. Aust NZ J Med. 26:1996;372-379
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1975;31-41
10. National Cancer Institute. Cancer therapy evaluation program, Common Toxicity Criteria, version 2.0. 1998;DCTD, NCI, NIH, DHHS, Bethesda
11. Cox J.D., Stetz J., Pajak T.F., et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346
12. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemoradiotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 91:1999;2081-2086
13. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 338:1998;1798-1804
14. Wendt T.G., Crabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer A randomized multi-centre study. J Clin Oncol. 16:1998;1318-1324
15. Weissberg J.B., Papac R.J., Sasaki C., et al. Randomised clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys. 17:1989;3-9
16. Cooper J.S., Thomas P.F., Forastiere A.A., et al. Post-operative concurrent radiochemotherapy in high-risk SCCA of the head and neck Initial report of RTOG 9501/Intergroup phase III trial. [Abstract] Proc ASCO. 21:2002;226a
17. Bernier J., Ozsahin M., Greiner R., et al. Results of EORTC phase III trial 22931 comparing, in postoperative setting, radiotherapy and radiotherapy combined to cisplatin in locally advanced head and neck squamous cell carcinoma. [Abstract] Int J Radiat Oncol Biol Phys. 51:(Suppl. 1):2001;1
18. Bachaud J.M., David J.M., Boussin G., et al. Combined postoperative radiotherapy and weekly cisplatin for locally advanced squamous cell carcinoma of the head and neck Preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys. 20:1991;243-246
19. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1999;1144-1153
20. Huang S.M., Li J., Armstrong E.A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 62:2002;4300-4306
21. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 51:2001;474-477
22. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:2000;5565-5570
23. Chinnaiyan P, Huang S, Armstrong E, et al. Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva) [Abstract]. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl.):S294
24. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63:2003;4009-4016
25. Corry J.F., Rischin D., Smith J.G., et al. Radiation with concurrent late chemotherapy intensification (chemoboost) for locally advanced head and neck cancer. Radiother Oncol. 54:2000;123-127